Immunotherapy for Alzheimer's disease

Richard C. Dodel, Harald Hampel, Yansheng Du

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Recent studies in murine models of Alzheimer's disease (AD) have found that active immunisation with amyloid-β peptide (Aβ) or passive immunisation with Aβ antibodies can lessen the severity of Aβ-induced neuritic plaque pathology through the activation of microglia. These antibodies can be detected in the serum and CSF. Whether they slow down or speed up the development and progression of AD has not been determined. Furthermore, the conditions that induce formation of such antibodies are unknown, or how specific they are to AD. However, the evidence suggests at least a potential beneficial role for some features of neuroinflammation in AD. A clinical phase II study of an active immunisation approach with AN1792 was started in 2001, but was recently suspended after some patients developed serious adverse events. These were most likely caused by the activation of the proinflammatory cascade. Immunotherapy approaches represent fascinating ways to test the amyloid hypothesis and may offer genuine opportunities to modify disease progression. This review focuses on immunisation strategies and details of the pathways involved in antibody clearance of Aβ.

Original languageEnglish
Pages (from-to)215-220
Number of pages6
JournalThe Lancet Neurology
Volume2
Issue number4
DOIs
StatePublished - Apr 1 2003

Fingerprint

Immunotherapy
Alzheimer Disease
Amyloid
Antibodies
Vaccination
Passive Immunization
Amyloid Plaques
Microglia
Antibody Formation
Disease Progression
Immunization
Pathology
Serum

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Immunotherapy for Alzheimer's disease. / Dodel, Richard C.; Hampel, Harald; Du, Yansheng.

In: The Lancet Neurology, Vol. 2, No. 4, 01.04.2003, p. 215-220.

Research output: Contribution to journalArticle

Dodel, Richard C. ; Hampel, Harald ; Du, Yansheng. / Immunotherapy for Alzheimer's disease. In: The Lancet Neurology. 2003 ; Vol. 2, No. 4. pp. 215-220.
@article{70b0f39a110044e1a86c7a7683293cf8,
title = "Immunotherapy for Alzheimer's disease",
abstract = "Recent studies in murine models of Alzheimer's disease (AD) have found that active immunisation with amyloid-β peptide (Aβ) or passive immunisation with Aβ antibodies can lessen the severity of Aβ-induced neuritic plaque pathology through the activation of microglia. These antibodies can be detected in the serum and CSF. Whether they slow down or speed up the development and progression of AD has not been determined. Furthermore, the conditions that induce formation of such antibodies are unknown, or how specific they are to AD. However, the evidence suggests at least a potential beneficial role for some features of neuroinflammation in AD. A clinical phase II study of an active immunisation approach with AN1792 was started in 2001, but was recently suspended after some patients developed serious adverse events. These were most likely caused by the activation of the proinflammatory cascade. Immunotherapy approaches represent fascinating ways to test the amyloid hypothesis and may offer genuine opportunities to modify disease progression. This review focuses on immunisation strategies and details of the pathways involved in antibody clearance of Aβ.",
author = "Dodel, {Richard C.} and Harald Hampel and Yansheng Du",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S1474-4422(03)00349-1",
language = "English",
volume = "2",
pages = "215--220",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "4",

}

TY - JOUR

T1 - Immunotherapy for Alzheimer's disease

AU - Dodel, Richard C.

AU - Hampel, Harald

AU - Du, Yansheng

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Recent studies in murine models of Alzheimer's disease (AD) have found that active immunisation with amyloid-β peptide (Aβ) or passive immunisation with Aβ antibodies can lessen the severity of Aβ-induced neuritic plaque pathology through the activation of microglia. These antibodies can be detected in the serum and CSF. Whether they slow down or speed up the development and progression of AD has not been determined. Furthermore, the conditions that induce formation of such antibodies are unknown, or how specific they are to AD. However, the evidence suggests at least a potential beneficial role for some features of neuroinflammation in AD. A clinical phase II study of an active immunisation approach with AN1792 was started in 2001, but was recently suspended after some patients developed serious adverse events. These were most likely caused by the activation of the proinflammatory cascade. Immunotherapy approaches represent fascinating ways to test the amyloid hypothesis and may offer genuine opportunities to modify disease progression. This review focuses on immunisation strategies and details of the pathways involved in antibody clearance of Aβ.

AB - Recent studies in murine models of Alzheimer's disease (AD) have found that active immunisation with amyloid-β peptide (Aβ) or passive immunisation with Aβ antibodies can lessen the severity of Aβ-induced neuritic plaque pathology through the activation of microglia. These antibodies can be detected in the serum and CSF. Whether they slow down or speed up the development and progression of AD has not been determined. Furthermore, the conditions that induce formation of such antibodies are unknown, or how specific they are to AD. However, the evidence suggests at least a potential beneficial role for some features of neuroinflammation in AD. A clinical phase II study of an active immunisation approach with AN1792 was started in 2001, but was recently suspended after some patients developed serious adverse events. These were most likely caused by the activation of the proinflammatory cascade. Immunotherapy approaches represent fascinating ways to test the amyloid hypothesis and may offer genuine opportunities to modify disease progression. This review focuses on immunisation strategies and details of the pathways involved in antibody clearance of Aβ.

UR - http://www.scopus.com/inward/record.url?scp=0038044258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038044258&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(03)00349-1

DO - 10.1016/S1474-4422(03)00349-1

M3 - Article

VL - 2

SP - 215

EP - 220

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 4

ER -